Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study (Arthritis & Rheumatology, 2017)

(untitled) - Emery, P; Taylor, P; Weinblatt, M; Tanaka, Y; Keystone, E; Dow, E; Higgs, R; Macias, W; Rocha, G; Rooney, T; Schlichting, D; Zuckerman, S; et al.